AtriCure Reports Second Quarter 2021 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results. “Our second quarter results were driven by outperformance across our business, as strong underlying demand returned and we saw continued progress toward...

Click to view original post